BioLife Solutions (BLFS) 10-Q 8 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 07, 2018
Document Information [Line Items]
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Entity Central Index Key	834,365
Trading Symbol	blfs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		18,499,767
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Balance Sheets (Current Period

Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 32,380,674	$ 6,663,318
Accounts receivable, trade, net of allowance for doubtful accounts of $0 and $5,575 at September 30, 2018 and December 31, 2017, respectively	2,699,342	1,021,315
Inventories	2,910,927	1,846,746
Prepaid expenses and other current assets	298,005	399,502
Total current assets	38,288,948	9,930,881
Property and equipment
Leasehold improvements	1,284,491	1,284,491
Furniture and computer equipment	705,948	682,466
Manufacturing and other equipment	1,510,729	1,148,006
Subtotal	3,501,168	3,114,963
Less: Accumulated depreciation	(2,234,286)	(2,008,927)
Net property and equipment	1,266,882	1,106,036
Investment in SAVSU	6,856,980	1,070,120
Long term deposits	36,166	36,166
Total assets	46,448,976	12,143,203
Current liabilities
Accounts payable	1,089,553	690,702
Accrued expenses and other current liabilities	162,981	200,548
Accrued compensation	712,615	491,432
Deferred rent	130,216	130,216
Total current liabilities	2,095,365	1,512,898
Deferred rent, long-term	386,113	492,207
Other long-term liabilities	37,855	45,512
Total liabilities	2,519,333	2,050,617
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 3,187 and 4,250 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	3	4
Common stock, $0.001 par value; 150,000,000 shares authorized, 18,237,425 and 14,021,422 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	18,237	14,021
Additional paid-in capital	115,775,040	84,036,444
Accumulated deficit	(71,863,637)	(73,957,883)
Total shareholders’ equity	43,929,643	10,092,586
Total liabilities and shareholders’ equity	$ 46,448,976	$ 12,143,203

Balance Sheets (Current Perio_2

Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounts receivable, allowance for doubtful accounts	$ 0	$ 5,575
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	1,000,000	1,000,000
Preferred stock, issued (in shares)	3,187	4,250
Preferred stock, outstanding (in shares)	3,187	4,250
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	18,237,425	14,021,422
Common stock, outstanding (in shares)	18,237,425	14,021,422
Series A Preferred Stock [Member]
Preferred stock, designated (in shares)	4,250	4,250
Preferred stock, outstanding (in shares)	3,187

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Product sales	$ 5,293,075	$ 2,963,411	$ 14,285,811	$ 7,887,377
Cost of product sales	1,606,303	1,095,724	4,506,911	2,980,965
Gross profit	3,686,772	1,867,687	9,778,900	4,906,412
Operating expenses
Research and development	312,000	293,093	983,066	898,451
Sales and marketing	725,201	488,688	1,977,871	1,547,087
General and administrative	1,454,573	1,118,251	4,198,474	3,298,461
Total operating expenses	2,491,774	1,900,032	7,159,411	5,743,999
Operating income (loss)	1,194,998	(32,345)	2,619,489	(837,587)
Other income (expenses), net
Interest income	79,773	103	120,728	227
Interest expense	(1,313)	(1,077)	(3,545)	(188,992)
Write-off of deferred financing costs		(67,664)		(67,664)
Amortization of debt discount				(155,996)
Loss from equity-method investment in SAVSU	(42,689)	(217,735)	(363,243)	(707,208)
Total other income (expenses), net	35,771	(286,373)	(246,060)	(1,119,633)
Net income (loss) before provision for income taxes	1,230,769	(318,718)	2,373,429	(1,957,220)
Income taxes
Net income (loss) after provision for income taxes	1,230,769	(318,718)	2,373,429	(1,957,220)
Less: Preferred stock dividends	(79,675)	(106,250)	(279,183)	(106,250)
Net income (loss) attributable to common stockholders	$ 1,151,094	$ (424,968)	$ 2,094,246	$ (2,063,470)
Basic net income (loss) per common share (in dollars per share)	$ 0.07	$ (0.03)	$ 0.13	$ (0.16)
Diluted net income (loss) per common share (in dollars per share)	$ 0.05	$ (0.03)	$ 0.10	$ (0.16)
Weighted average shares outstanding used to compute basic earnings per share (in shares)	17,273,412	13,238,248	15,529,026	13,102,238
Weighted average shares outstanding used to compute diluted earnings per share (in shares)	23,656,633	13,238,248	21,051,219	13,102,238

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities
Net income	$ 2,373,429	$ (1,957,220)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Depreciation	244,927	259,895
Stock-based compensation expense	1,130,945	957,711
Stock issued for services		71,250
Write-off of deferred financing costs		67,664
Amortization of deferred rent related to lease incentives	(95,248)	(95,249)
Amortization of debt discount		155,996
Loss from equity-method investment in SAVSU	363,243	707,208
Change in operating assets and liabilities
Accounts receivable, trade	(1,678,027)	(159,851)
Inventories	(1,064,181)	(103,274)
Prepaid expenses and other current assets	(48,606)	(101,479)
Accounts payable	342,875	(227,732)
Accrued compensation and other current liabilities	204,653	138,885
Accrued interest		152,143
Deferred rent	(11,490)	(63,836)
Net cash provided by (used in) operating activities	1,762,520	(197,889)
Cash flows from investing activities
Investment in SAVSU	(6,000,000)
Purchase of property and equipment	(339,068)	(91,443)
Net cash used in investing activities	(6,339,068)	(91,443)
Cash flows from financing activities
Proceeds from private equity transaction	19,999,994
Proceeds from related party debt		1,000,000
Payments on equipment loan	(9,267)	(10,628)
Payments on capital lease obligations	(9,812)	(7,631)
Proceeds from exercise of common stock options and warrants	11,724,247	784,273
Payments of preferred stock dividends	(305,758)
Payments of costs related to stock issuances	(42,500)	(9,303)
Payments for redemption of preferred stock	(1,063,000)
Deferred costs related to potential stock issuance		(42,664)
Net cash provided by financing activities	30,293,904	1,714,047
Net increase in cash and cash equivalents	25,717,356	1,424,715
Cash and cash equivalents - beginning of period	6,663,318	1,405,826
Cash and cash equivalents - end of period	32,380,674	2,830,541
Non-cash investing and financing activities
Series A preferred stock dividends accrued not yet paid	79,675	106,250
Stock issued for services provided in prior period included in liabilities at year-end	35,625	35,624
Receivables converted to equity investment in SAVSU	150,103
Preferred stock issued on conversion of related party note payable and accrued interest		4,250,000
Capital lease obligations incurred for purchases of equipment		52,327
Purchase of equipment with debt	17,604	39,243
Legal fees for private equity transaction not yet paid	42,500
Purchase of property and equipment not yet paid	$ 49,101

Statements of Shareholders' Equ

Statements of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	4,250	14,021,422
Balance at Dec. 31, 2017	$ 4	$ 14,021	$ 84,036,444	$ (73,957,883)	$ 10,092,586
Redemption of preferred stock (in shares)	(1,063)
Redemption of preferred stock	$ (1)		(1,062,999)		(1,063,000)
Stock based compensation			1,130,945		1,130,945
Stock issued for private equity transaction, net of $85,000 legal fees (in shares)		1,428,571
Stock issued for private equity transaction, net of $85,000 legal fees		$ 1,429	19,913,565		19,914,994
Stock option/warrant exercises (in shares)		2,684,899
Stock option/warrant exercises		$ 2,684	11,721,563		11,724,247
Stock issued – on vested RSUs (in shares)		96,594
Stock issued – on vested RSUs		$ 97	(97)
Stock issued for services (in shares)		5,939
Stock issued for services		$ 6	35,619		35,625
Preferred stock dividends				(279,183)	(279,183)
Net income				2,373,429	2,373,429
Balance (in shares) at Sep. 30, 2018	3,187	18,237,425
Balance at Sep. 30, 2018	$ 3	$ 18,237	$ 115,775,040	$ (71,863,637)	$ 43,929,643

Statements of Shareholders' E_2

Statements of Shareholders' Equity (Unaudited) (Parentheticals)	9 Months Ended
	Sep. 30, 2018USD ($)
Additional Paid-in Capital [Member]
Stock issuance costs	$ 85,000

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Organization and Significant Accounting Policies Business BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is the leading developer, manufacturer and supplier of proprietary, clinical-grade biopreservation media for cells and tissues. Our HypoThermosol® hypothermic storage and CryoStor® cryopreservation freeze media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function. Basis of Presentation We have prepared the accompanying unaudited financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not may 10 December 31, 2017 There have been no 10 December 31, 2017, No. 2014 09, 606 Significant Accounting Policies Update Revenue Recognition On January 1, 2018, No. 2014 09, 606 January 1, 2018. January 1, 2018 not 605, not no To determine revenue recognition for contractual arrangements that we determine are within the scope of Topic 606, five five not one We invoice and receive payment from our customers after we recognize revenue, resulting in receivables from our customers that are presented as accounts receivable on our balance sheet. Accounts receivable consist of short-term amounts due from our customers (generally 30 90 Equity Method Investments We account for our ownership in our SAVSU Technologies, Inc. joint venture (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not 20% 50%, January 22, 2018, 35%, December 31, 2016, 35% December 31, 2017. $6 44.4% September 30, 2018. 18 56% not 1,000,000 $23 three nine September 30, 2018, $16,000 $1.1 three nine September 30, 2017, $0.5 $1.6 Concentrations of credit risk and business risk In the three nine September 30, 2018, 41% three 28% two three nine September 30, 2017, 22% two 10% one No 10% three nine September 30, 2018 2017. September 30, 2018, four 54% December 31, 2017, two 41% Revenue from customers located in foreign countries represented 8% 10% three nine September 30, 2018, 16% 17% three nine September 30, 2017, Recent Accounting Pronouncements In August 2016, No. 2016 15, 230 2016 15 January 1, 2018, no In February 2016, No. 2016 02, 842 2016 02 2016 02. December 15, 2018. 2016 02 January 1, 2019. The FASB has issued several additional ASUs that provide additional clarification to certain issues existing after the original ASU was released. In July 2018, 2018 11 842 not July 2018, 2018 10 842 sixteen 2016 02. 2018 11 2018 10 2016 02. 2018 11 2018 10 In January 2016, No. 2016 01, 825 2016 01 January 1, 2018, no With the exception of the new standards discussed above, there have been no not

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. Fair Value Measurement In accordance with FASB ASC Topic 820, 820” 820 820 three Level 1 Level 2 1 not Level 3 As of September 30, 2018 December 31, 2017, not The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of September 30, 2018 December 31, 2017, three As of September 30, 2018 Level 1 Level 2 Total Bank deposits $ 32,327,287 $ — $ 32,327,287 Money market funds 53,387 — 53,387 Total cash and cash equivalents $ 32,380,674 $ — $ 32,380,674 As of December 31, 2017 Level 1 Level 2 Total Bank deposits $ 6,610,183 $ — $ 6,610,183 Money market funds 53,135 — 53,135 Total cash and cash equivalents $ 6,663,318 $ — $ 6,663,318 The fair values of bank deposits and money market funds classified as Level 1 no 2 3 not 1 2 nine September 30, 2018 twelve December 31, 2017.

Note 3 - Inventory

Note 3 - Inventory	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventory Inventory consists of the following at September 30, 2018 December 31, 2017: September 30, 2018 December 31, 2017 Raw materials $ 1,168,969 $ 582,816 Work in progress 830,991 453,890 Finished goods 910,967 810,040 Total $ 2,910,927 $ 1,846,746

Note 4 - Deferred Rent

Note 4 - Deferred Rent	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Deferred Rent [Text Block]	4. Deferred Rent Deferred rent consists of the following at September 30, 2018 December 31, 2017: September 30, 2018 December 31, 2017 Landlord-funded leasehold improvements $ 1,124,790 $ 1,124,790 Less accumulated amortization (724,773 ) (629,525 ) Total 400,017 495,265 Straight line rent adjustment 116,312 127,158 Total deferred rent $ 516,329 $ 622,423 During the three nine September 30, 2018, $31,749 $95,248, three nine September 30, 2017, $31,749 $95,249, Straight line rent adjustment represents the difference between cash rent payments and the recognition of rent expense on a straight-line basis over the terms of the lease.

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	5. Share-based Compensation Service Vesting-Based Stock Options The following is a summary of service vesting-based related stock option activity for the nine September 30, 2018, September 30, 2018: Nine Month Period Ended September 30, 2018 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 2,390,012 $ 1.85 Granted — $ — Exercised (267,055 ) $ 1.30 Forfeited (15,627 ) $ 4.34 Expired — $ — Outstanding service vesting-based at September 30, 2018 2,107,330 $ 1.90 Service vesting-based options exercisable at September 30, 2018 1,622,980 $ 1.83 We recognized stock compensation expense related to service vesting-based options of $146,567 $146,355 three September 30, 2018 2017, $448,882 $463,217 nine September 30, 2018 September 30, 2017, September 30, 2018, $32,868,498 $25,429,311 September 30, 2018. three September 30, 2018 2017 $2,094,344 none, nine September 30, 2018 2017 $3,088,117 $91,817, three September 30, 2018 2017 none nine September 30, 2018 2017 none $1.13 September 30, 2018, 5.8 5.5 September 30, 2018 $678,908 1.6 Performance-based Stock Options The Company’s Board of Directors implemented a Management Performance Bonus Plan for 2017. December 31, 2017, 1,000,000 may $1.64, 2017 50% 2017, 50% one not no February 27, 2018, 2017 999,997 50% March 8, 2018 50% March 8, 2019. The following is a summary of performance-based stock option activity for the nine September 30, 2018, September 30, 2018: Nine Month Period Ended September 30, 2018 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 999,997 $ 1.64 Granted — $ — Exercised (35,000 ) $ 1.64 Outstanding performance-based at September 30, 2018 964,997 $ 1.64 Performance-based options exercisable at September 30, 2018 465,001 $ 1.64 We recognized stock compensation expense related to performance-based options of $128,296 $128,298 three September 30, 2018 2017, $380,705 $380,708 nine September 30, 2018 2017, September 30, 2018, $15,304,852 $7,374,916 September 30, 2018. three nine September 30, 2018 none $285,250, no three nine September 30, 2017. September 30, 2018, 3.2 September 30, 2018 $128,296 0.3 The fair value of share-based payments made with stock options to employees and non-employee directors was estimated on the measurement date using the Black-Scholes model using the following weighted average assumptions. Three Month Period Ended Nine Month Period Ended September 30, September 30, 2018 2017 2018 2017 Risk free interest rate N/A N/A N/A 2.07 % Dividend yield N/A N/A N/A 0.0 % Expected term (in years) N/A N/A N/A 5.18 Volatility N/A N/A N/A 75 % Restricted Stock The following is a summary of restricted stock activity for the nine September 30, 2018, September 30, 2018: Nine Month Period Ended September 30, 2018 Number of Grant-Date Outstanding at beginning of year 237,926 $ 1.79 Granted 181,268 $ 7.02 Vested (96,593 ) $ 1.80 Forfeited (21,128 ) $ 3.32 Outstanding at September 30, 2018 301,473 $ 4.82 The aggregate fair value of the awards granted during the three nine September 30, 2018 $147,900 $1,272,948, three nine September 30, 2017 none $364,936, three September 30, 2018 2017 $392,858 $38,567, nine September 30, 2018 2017 $873,594 $99,725, We recognized stock compensation expense of $108,277 $39,290 three September 30, 2018 2017, $301,058 $113,786 nine September 30, 2018 2017, September 30, 2018, $1,245,763 3.2 We recorded total stock compensation expense for the three nine September 30, 2018 2017, Three Month Period Ended Nine Month Period Ended September 30, September 30, 2018 2017 2018 2017 Research and development costs $ 64,970 $ 59,434 $ 195,316 $ 177,514 Sales and marketing costs 64,152 55,402 201,907 173,072 General and administrative costs 194,764 156,621 576,718 479,803 Cost of product sales 59,254 42,486 157,004 127,322 Total $ 383,140 $ 313,943 $ 1,130,945 $ 957,711

Note 6 - Warrants

Note 6 - Warrants	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Warrants [Text Block]	6. Warrants At September 30, 2018 December 31, 2017, 4,306,005 6,688,849 $4.37 $4.50, three nine September 30, 2018, 557,153 2,382,844 $4.75 $2.6 $11.3 November 7, 2018, 225,000 $4.75, $1.1 March 2021 May 2021.

Note 7 - Income Taxes

Note 7 - Income Taxes	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7. Income Taxes We have recorded a full valuation allowance against our deferred tax assets. As we trend towards positive net income, we will continue to assess our valuation allowance. Based on all available evidence, we determined that we have not September 30, 2018. may

Note 8 - Earnings Per Share

Note 8 - Earnings Per Share	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	8. Earnings Per Share Basic earnings per share is calculated by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding as determined by the treasury method during the period. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. For the three nine September 30, 2018, three nine September 30, 2017, 3.4 7.4 259,000 The following table shows the calculation of basic and diluted earnings per shares: Three Month Period Ended Nine Month Period Ended September 30, September 30, 2018 2017 2018 2017 Numerator: Net income (loss) attributable to common stockholders $ 1,151,094 $ (424,968 ) $ 2,094,246 $ (2,063,470 ) Denominator: Weighted average basic shares outstanding 17,273,412 13,238,248 15,529,026 13,102,238 Effect of dilutive securities 6,383,221 — 5,522,193 — Weighted average diluted shares 23,656,633 13,238,248 21,051,219 13,102,238 Basic earnings per share $ 0.07 $ (0.03 ) $ 0.13 $ (0.16 ) Diluted earnings per share $ 0.05 $ (0.03 ) $ 0.10 $ (0.16 )

Note 9 - Commitments & Continge

Note 9 - Commitments & Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments & Contingencies Leases We lease approximately 30,000 July 31, 2021 two five first August 1, 2021, second first $59,000 September 30, 2018, August October Employment Agreements We have employment agreements with our Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice President of Operations, Vice President of Marketing, and Vice President of Sales. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none

Note 10 - Preferred Stock

Note 10 - Preferred Stock	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Preferred Stock As of September 30, 2018, $79,675 September 30, 2018. October 1, 2018. 3,187 September 30, 2018.

Note 11 - Revenue

Note 11 - Revenue	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	11. Revenue We currently operate as one The following table disaggregates revenue by market segment and distributors: Three Month Period Ended Nine Month Period Ended September 30, September 30, 2018 2017 2018 2017 Net product sales: Regenerative medicine $ 2,875,861 $ 1,599,916 $ 7,964,499 $ 3,734,724 Distributors 1,886,885 759,826 4,621,280 2,213,880 Drug discovery 275,747 320,206 915,745 1,087,014 BioBanking 254,582 283,463 784,287 851,759 Total $ 5,293,075 $ 2,963,411 $ 14,285,811 $ 7,887,377

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation We have prepared the accompanying unaudited financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not may 10 December 31, 2017 There have been no 10 December 31, 2017, No. 2014 09, 606
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition On January 1, 2018, No. 2014 09, 606 January 1, 2018. January 1, 2018 not 605, not no To determine revenue recognition for contractual arrangements that we determine are within the scope of Topic 606, five five not one We invoice and receive payment from our customers after we recognize revenue, resulting in receivables from our customers that are presented as accounts receivable on our balance sheet. Accounts receivable consist of short-term amounts due from our customers (generally 30 90
Equity Method Investments [Policy Text Block]	Equity Method Investments We account for our ownership in our SAVSU Technologies, Inc. joint venture (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not 20% 50%, January 22, 2018, 35%, December 31, 2016, 35% December 31, 2017. $6 44.4% September 30, 2018. 18 56% not 1,000,000 $23 three nine September 30, 2018, $16,000 $1.1 three nine September 30, 2017, $0.5 $1.6
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of credit risk and business risk In the three nine September 30, 2018, 41% three 28% two three nine September 30, 2017, 22% two 10% one No 10% three nine September 30, 2018 2017. September 30, 2018, four 54% December 31, 2017, two 41% Revenue from customers located in foreign countries represented 8% 10% three nine September 30, 2018, 16% 17% three nine September 30, 2017,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2016, No. 2016 15, 230 2016 15 January 1, 2018, no In February 2016, No. 2016 02, 842 2016 02 2016 02. December 15, 2018. 2016 02 January 1, 2019. The FASB has issued several additional ASUs that provide additional clarification to certain issues existing after the original ASU was released. In July 2018, 2018 11 842 not July 2018, 2018 10 842 sixteen 2016 02. 2018 11 2018 10 2016 02. 2018 11 2018 10 In January 2016, No. 2016 01, 825 2016 01 January 1, 2018, no With the exception of the new standards discussed above, there have been no not

Note 2 - Fair Value Measureme_2

Note 2 - Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	As of September 30, 2018 Level 1 Level 2 Total Bank deposits $ 32,327,287 $ — $ 32,327,287 Money market funds 53,387 — 53,387 Total cash and cash equivalents $ 32,380,674 $ — $ 32,380,674 As of December 31, 2017 Level 1 Level 2 Total Bank deposits $ 6,610,183 $ — $ 6,610,183 Money market funds 53,135 — 53,135 Total cash and cash equivalents $ 6,663,318 $ — $ 6,663,318

Note 3 - Inventory (Tables)

Note 3 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2018 December 31, 2017 Raw materials $ 1,168,969 $ 582,816 Work in progress 830,991 453,890 Finished goods 910,967 810,040 Total $ 2,910,927 $ 1,846,746

Note 4 - Deferred Rent (Tables)

Note 4 - Deferred Rent (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Deferred Rent [Table Text Block]	September 30, 2018 December 31, 2017 Landlord-funded leasehold improvements $ 1,124,790 $ 1,124,790 Less accumulated amortization (724,773 ) (629,525 ) Total 400,017 495,265 Straight line rent adjustment 116,312 127,158 Total deferred rent $ 516,329 $ 622,423

Note 5 - Share-based Compensa_2

Note 5 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Nine Month Period Ended September 30, 2018 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 2,390,012 $ 1.85 Granted — $ — Exercised (267,055 ) $ 1.30 Forfeited (15,627 ) $ 4.34 Expired — $ — Outstanding service vesting-based at September 30, 2018 2,107,330 $ 1.90 Service vesting-based options exercisable at September 30, 2018 1,622,980 $ 1.83 Nine Month Period Ended September 30, 2018 Wtd. Avg. Exercise Options Price Outstanding at beginning of year 999,997 $ 1.64 Granted — $ — Exercised (35,000 ) $ 1.64 Outstanding performance-based at September 30, 2018 964,997 $ 1.64 Performance-based options exercisable at September 30, 2018 465,001 $ 1.64
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Month Period Ended Nine Month Period Ended September 30, September 30, 2018 2017 2018 2017 Risk free interest rate N/A N/A N/A 2.07 % Dividend yield N/A N/A N/A 0.0 % Expected term (in years) N/A N/A N/A 5.18 Volatility N/A N/A N/A 75 %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Nine Month Period Ended September 30, 2018 Number of Grant-Date Outstanding at beginning of year 237,926 $ 1.79 Granted 181,268 $ 7.02 Vested (96,593 ) $ 1.80 Forfeited (21,128 ) $ 3.32 Outstanding at September 30, 2018 301,473 $ 4.82
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Month Period Ended Nine Month Period Ended September 30, September 30, 2018 2017 2018 2017 Research and development costs $ 64,970 $ 59,434 $ 195,316 $ 177,514 Sales and marketing costs 64,152 55,402 201,907 173,072 General and administrative costs 194,764 156,621 576,718 479,803 Cost of product sales 59,254 42,486 157,004 127,322 Total $ 383,140 $ 313,943 $ 1,130,945 $ 957,711

Note 8 - Earnings Per Share (Ta

Note 8 - Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Month Period Ended Nine Month Period Ended September 30, September 30, 2018 2017 2018 2017 Numerator: Net income (loss) attributable to common stockholders $ 1,151,094 $ (424,968 ) $ 2,094,246 $ (2,063,470 ) Denominator: Weighted average basic shares outstanding 17,273,412 13,238,248 15,529,026 13,102,238 Effect of dilutive securities 6,383,221 — 5,522,193 — Weighted average diluted shares 23,656,633 13,238,248 21,051,219 13,102,238 Basic earnings per share $ 0.07 $ (0.03 ) $ 0.13 $ (0.16 ) Diluted earnings per share $ 0.05 $ (0.03 ) $ 0.10 $ (0.16 )

Note 11 - Revenue (Tables)

Note 11 - Revenue (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Month Period Ended Nine Month Period Ended September 30, September 30, 2018 2017 2018 2017 Net product sales: Regenerative medicine $ 2,875,861 $ 1,599,916 $ 7,964,499 $ 3,734,724 Distributors 1,886,885 759,826 4,621,280 2,213,880 Drug discovery 275,747 320,206 915,745 1,087,014 BioBanking 254,582 283,463 784,287 851,759 Total $ 5,293,075 $ 2,963,411 $ 14,285,811 $ 7,887,377

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Details Textual)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018USD ($)shares	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)shares	Sep. 30, 2017USD ($)	Dec. 31, 2017	Sep. 05, 2018	Jan. 22, 2018
Net Income (Loss) Attributable to Parent, Total	$ 1,230,769	$ (318,718)	$ 2,373,429	$ (1,957,220)
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	41.00%	22.00%	28.00%	10.00%
Number of Major Customers	3	2	2	1
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Foreign Countries [Member]
Concentration Risk, Percentage	8.00%	16.00%	10.00%	17.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage			54.00%		41.00%
Number of Major Customers			4		2
SAVSU [Member]
Net Income (Loss) Attributable to Parent, Total	$ (16,000)	$ (500,000)	$ (1,100,000)	$ (1,600,000)
SAVSU [Member]
Equity Method Investment, Ownership Percentage						44.40%	35.00%
Payments to Acquire Equity Method Investments			$ 6,000,000
Purchase Option, Term			1 year 180 days
Purchase Option, Additional Ownership Percentage to be Acquired			56.00%
Purchase Option, Consideration Transferred, Equity Interests Issuable, Shares | shares	1,000,000		1,000,000
Purchase Option, Consideration Transferred, Equity Interests Issuable	$ 23,000,000		$ 23,000,000

Note 2 - Fair Value Measureme_3

Note 2 - Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure	$ 0	$ 0

Note 2 - Fair Value Measureme_4

Note 2 - Fair Value Measurement - Financial Assets on Recurring Basis (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Fair Value, Inputs, Level 2 [Member]
Total cash and cash equivalents	$ 0	$ 0
Fair Value, Measurements, Recurring [Member]
Total cash and cash equivalents	32,380,674	6,663,318
Fair Value, Measurements, Recurring [Member] | Bank Time Deposits [Member]
Cash and cash equivalents	32,327,287	6,610,183
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Cash and cash equivalents	53,387	53,135
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total cash and cash equivalents	32,380,674	6,663,318
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Bank Time Deposits [Member]
Cash and cash equivalents	32,327,287	6,610,183
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Cash and cash equivalents	53,387	53,135
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total cash and cash equivalents
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Bank Time Deposits [Member]
Cash and cash equivalents
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Cash and cash equivalents

Note 3 - Inventory - Summary of

Note 3 - Inventory - Summary of Inventory (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Raw materials	$ 1,168,969	$ 582,816
Work in progress	830,991	453,890
Finished goods	910,967	810,040
Total	$ 2,910,927	$ 1,846,746

Note 4 - Deferred Rent (Details

Note 4 - Deferred Rent (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Amortization of Deferred Rent	$ 31,749	$ 31,749	$ 95,248	$ 95,249

Note 4 - Deferred Rent - Summar

Note 4 - Deferred Rent - Summary of Deferred Rent (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Landlord-funded leasehold improvements	$ 1,124,790	$ 1,124,790
Less accumulated amortization	(724,773)	(629,525)
Total	400,017	495,265
Straight line rent adjustment	116,312	127,158
Total deferred rent	$ 516,329	$ 622,423

Note 5 - Share-based Compensa_3

Note 5 - Share-based Compensation (Details Textual) - USD ($)	Feb. 27, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Allocated Share-based Compensation Expense, Total		$ 383,140	$ 313,943	$ 1,130,945	$ 957,711
Employee Stock Option [Member]
Allocated Share-based Compensation Expense, Total		146,567	146,355	448,882	463,217
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		32,868,498		32,868,498
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		25,429,311		25,429,311
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 2,094,344	$ 0	$ 3,088,117	$ 91,817
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0	$ 0	$ 0	$ 1.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				5 years 292 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term				5 years 182 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 678,908		$ 678,908
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 219 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				267,055
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				35,000
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member]
Allocated Share-based Compensation Expense, Total		128,296	$ 128,298	$ 380,705	$ 380,708
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		15,304,852		15,304,852
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		7,374,916		7,374,916
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		0		$ 285,250
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				3 years 73 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term				3 years 73 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		128,296		$ 128,296
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				109 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price						$ 1.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	999,997
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			0		0
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting on Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Vesting One Year After Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Restricted Stock [Member]
Allocated Share-based Compensation Expense, Total		108,277	$ 39,290	$ 301,058	$ 113,786
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		1,245,763		$ 1,245,763
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				3 years 73 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value		147,900	0	$ 1,272,948	364,936
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 392,858	$ 38,567	$ 873,594	$ 99,725

Note 5 - Share-based Compensa_4

Note 5 - Share-based Compensation - Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Employee Stock Option [Member]
Outstanding at beginning of year (in shares) | shares	2,390,012
Outstanding at beginning of year, weighted average exercise price (in dollars per share) | $ / shares	$ 1.85
Granted (in shares) | shares
Granted, weighted average exercise price (in dollars per share) | $ / shares
Exercised (in shares) | shares	(267,055)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 1.30
Forfeited (in shares) | shares	(15,627)
Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 4.34
Expired (in shares) | shares
Expired, weighted average exercise price (in dollars per share) | $ / shares
Outstanding service vesting-based at September 30, 2018 (in shares) | shares	2,107,330
Outstanding service vesting-based at September 30, 2018 (in dollars per share) | $ / shares	$ 1.90
Service vesting-based options exercisable at September 30, 2018 (in shares) | shares	1,622,980
Service vesting-based options exercisable at September 30, 2018 (in dollars per share) | $ / shares	$ 1.83
Performance Shares [Member]
Outstanding at beginning of year (in shares) | shares	999,997
Outstanding at beginning of year, weighted average exercise price (in dollars per share) | $ / shares	$ 1.64
Granted (in shares) | shares
Granted, weighted average exercise price (in dollars per share) | $ / shares
Exercised (in shares) | shares	(35,000)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 1.64
Outstanding service vesting-based at September 30, 2018 (in shares) | shares	964,997
Outstanding service vesting-based at September 30, 2018 (in dollars per share) | $ / shares	$ 1.64
Service vesting-based options exercisable at September 30, 2018 (in shares) | shares	465,001
Service vesting-based options exercisable at September 30, 2018 (in dollars per share) | $ / shares	$ 1.64

Note 5 - Share-based Compensa_5

Note 5 - Share-based Compensation - Fair Value Assumptions (Details) - Employee Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Risk free interest rate				2.07%
Dividend yield				0.00%
Expected term (Year)				5 years 65 days
Volatility				75.00%

Note 5 - Share-based Compensa_6

Note 5 - Share-based Compensation - Restricted Stock Activity (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Outstanding at beginning of year (in shares) | shares	237,926
Outstanding at beginning of year (in dollars per share) | $ / shares	$ 1.79
Unvested granted (in shares) | shares	181,268
Granted, grant date fair value (in dollars per share) | $ / shares	$ 7.02
Vested (in shares) | shares	(96,593)
Vested, grant date fair value (in dollars per share) | $ / shares	$ 1.80
Unvested forfeited (in shares) | shares	(21,128)
Forfeited, grant date fair value (in dollars per share) | $ / shares	$ 3.32
Outstanding at September 30, 2018 (in shares) | shares	301,473
Outstanding at September 30, 2018 (in dollars per share) | $ / shares	$ 4.82

Note 5 - Share-based Compensa_7

Note 5 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock compensation expense	$ 383,140	$ 313,943	$ 1,130,945	$ 957,711
Research and Development Expense [Member]
Stock compensation expense	64,970	59,434	195,316	177,514
Selling and Marketing Expense [Member]
Stock compensation expense	64,152	55,402	201,907	173,072
General and Administrative Expense [Member]
Stock compensation expense	194,764	156,621	576,718	479,803
Cost of Sales [Member]
Stock compensation expense	$ 59,254	$ 42,486	$ 157,004	$ 127,322

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	Nov. 07, 2018	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Class of Warrant or Right, Outstanding		4,306,005	4,306,005	6,688,849
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.37	$ 4.37	$ 4.50
Class of Warrant or Right, Exercised During Period		557,153	2,382,844
Class of Warrant or Right, Exercised During Period, Exercise Price		$ 4.75	$ 4.75
Proceeds from Warrant Exercises		$ 2.6	$ 11.3
Subsequent Event [Member]
Class of Warrant or Right, Exercised During Period	225,000
Class of Warrant or Right, Exercised During Period, Exercise Price	$ 4.75
Proceeds from Warrant Exercises	$ 1.1

Note 8 - Earnings Per Share (De

Note 8 - Earnings Per Share (Details Textual) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,400,000	3,400,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,400,000	7,400,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	259,000	259,000

Note 8 - Earnings Per Share - C

Note 8 - Earnings Per Share - Calculation of Diluted Shares (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net income (loss) attributable to common stockholders	$ 1,151,094	$ (424,968)	$ 2,094,246	$ (2,063,470)
Weighted average shares outstanding used to compute basic earnings per share (in shares)	17,273,412	13,238,248	15,529,026	13,102,238
Effect of dilutive securities (in shares)	6,383,221		5,522,193
Weighted average diluted shares (in shares)	23,656,633	13,238,248	21,051,219	13,102,238
Basic net income (loss) per common share (in dollars per share)	$ 0.07	$ (0.03)	$ 0.13	$ (0.16)
Diluted net income (loss) per common share (in dollars per share)	$ 0.05	$ (0.03)	$ 0.10	$ (0.16)

Note 9 - Commitments & Contin_2

Note 9 - Commitments & Contingencies (Details Textual) - Bothell, Washington Headquarters [Member]	3 Months Ended
	Sep. 30, 2018USD ($)ft²
Area of Real Estate Property | ft²	30,000
Lessee, Operating Lease, Renewal Term	5 years
Monthly Base Rent Expense | $	$ 59,000

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Preferred Stock, Shares Outstanding, Ending Balance	3,187	4,250
Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	3,187
Series A Preferred Stock [Member] | Accrued Liabilities Current [Member]
Dividends Payable, Current	$ 79,675

Note 11 - Revenue (Details Text

Note 11 - Revenue (Details Textual)	9 Months Ended
	Sep. 30, 2018
Number of Operating Segments	1

Note 11 - Revenue - Disaggregat

Note 11 - Revenue - Disaggregated Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net product sales	$ 5,293,075	$ 2,963,411	$ 14,285,811	$ 7,887,377
Regenerative Medicine [Member]
Net product sales	2,875,861	1,599,916	7,964,499	3,734,724
Distribution Service [Member]
Net product sales	1,886,885	759,826	4,621,280	2,213,880
Drug Discovery [Member]
Net product sales	275,747	320,206	915,745	1,087,014
BioBanking [Member]
Net product sales	$ 254,582	$ 283,463	$ 784,287	$ 851,759